A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Cilastatin/imipenem/relebactam (Primary)
- Indications Gram-negative infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 09 Oct 2017 Status changed from not yet recruiting to recruiting.
- 07 Sep 2017 Planned initiation date changed from 16 Sep 2017 to 11 Nov 2017.
- 14 Jun 2017 New trial record